Health ConditionsCushing's disease is an endocrine disorder characterized by increased adrenocorticotropic hormone (ACTH) production from the anterior pituitary, leading to excess cortisol release from the adrenal glands. The term Cushing's disease is specifically applied to ACTH-secreting pituitary tumors. This distinguishes it from the broader category of Cushing's syndrome, which describes any cause of chronically elevated cortisol.
Chronic glucocorticoid excess, or Cushing's syndrome, may be due to ACTH-dependent (80% of cases) or ACTH-independent (20% of cases) causes. The latter are mainly due to benign (60%) or malignant (40%) adrenal tumors. ACTH overproduction may be of pituitary origin (85% of cases) or result from ectopic tumor secretion (15% of cases).
Cushing's disease is a rare condition, only affecting 10 to 15 people per million every year. It is more common in women and occurs most often in people between the ages of 20 and 50. It accounts for approximately 15% of all pituitary adenomas and has a female predominance of 4:1.
Normally, the hypothalamus secretes corticotropin-releasing hormone (CRH), which stimulates the pituitary gland to secrete adrenocorticotropic hormone (ACTH). ACTH travels to the adrenal glands, where it targets cells in the adrenal cortex. The adrenal cortex is the outer part of the adrenal gland and is subdivided into three layers β the zona glomerulosa, the zona fasciculata, and the zona reticularis. The zona fasciculata is the middle zone and also the widest zone, and ACTH specifically stimulates cells in this zone to secrete cortisol β a class of steroids called glucocorticoids.
Cushing's disease is the result of excess secretion of ACTH by a benign monoclonal pituitary adenoma. The excessive secretion of ACTH stimulates secretion of cortisol by the adrenal glands, resulting in supraphysiological levels of circulating cortisol. The adenoma cells are partially resistant to physiological stimuli (i.e., glucocorticoids) and do not respond to the normal negative feedback loop. In contrast, corticotroph adenomas are inappropriately sensitive to CRH and AVP (arginine vasopressin).
Cushing's disease is caused by a tumor or excess growth (hyperplasia) of the pituitary gland. The pituitary gland is located just below the base of the brain. A type of pituitary tumor called an adenoma is the most common cause; an adenoma is a benign tumor (not a cancer).
A key feature is that many patients with Cushing's disease do not present with bitemporal hemianopsia because most lesions are pituitary microadenomas (less than 10 mm in size). On presentation, over 50% of the patients with Cushing's disease have pituitary microadenoma with a diameter smaller than 5 mm, which are difficult to see through imaging. Of these, only 10% are large enough to produce a mass effect on the cerebral tissue or to affect the structure of the sellar region.
The clinical presentation of Cushing's syndrome varies, in part related to the extent and duration of cortisol excess. When hypercortisolism is severe, its signs and symptoms are unmistakable. However, most of the signs and symptoms of Cushing's syndrome are common in the general population (e.g., hypertension and weight gain) and not all are present in every patient. In addition to classical features of glucocorticoid excess, such as proximal muscle weakness and wide purple striae, patients may present with the associated co-morbidities including cardiovascular disease, thromboembolic disease, psychiatric and cognitive deficits, and infections.
The characteristic physical signs include:
The primary clinical signs and symptoms include changes in body habitus (moon facies, increased supraclavicular fat pad and dorsicervical hump), hirsutism, skin changes (easy bruising, purplish striae, reddening of the cheeks), generalized weakness and fatigue, wasting of musculature (particularly proximal muscles), menstrual disorders, decreased fertility and/or libido, hypertension, weight gain, decreased insulin sensitivity with disorders in glucose metabolism (including impaired glucose tolerance and diabetes mellitus), dyslipidemias (including elevated levels of triglycerides and low HDL cholesterol), mental disorders ranging from mood and behavior disorders to depression and psychosis, sleep disturbances, osteopenia/osteoporosis, and immunosuppression with increased risk for infections.
The impairment of glucose metabolism is a common complication of chronic exposure to endogenous and exogenous glucocorticoid excess, contributing to morbidity and mortality in patients with Cushing's syndrome. Chronic hypercortisolism may have pleiotropic effects on all major peripheral tissues governing glucose homeostasis, leading to increased insulin resistance and decreased insulin secretion, acting through both genomic and nongenomic mechanisms in a context-specific and cell-/organ-dependent manner.
Cushing's syndrome can affect blood sugar levels even if a person does not have diabetes or other risk factors for type 2 diabetes. Among people with Cushing's syndrome, 43% to 84% will experience a disruption in how their body processes blood sugar due to reduced insulin action, and this is associated with an increased risk of metabolic syndrome and cardiovascular death.
In patients with Cushing's disease, there is an increased prevalence of cardiovascular diseases and/or risk factors including visceral obesity, insulin resistance, atherosclerosis, arterial hypertension, dyslipidaemia, hypercoagulability, as well as structural and functional changes in the heart, like cardiac hypertrophy and left ventricular dysfunction. Notably, these demonstrate limited reversibility even after remission.
Hypertension is a frequent feature of endogenous Cushing's syndrome with a prevalence of approximately 80% in adults. It is even more common (95%) in ectopic Cushing's syndrome, whereas in children and adolescents it is less common (about 47%).
Hypercortisolemia increases clotting factors including factor VIII, fibrinogen, and von Willebrand factor, and reduces fibrinolytic activity by elevated plasminogen activator inhibitor-1 and antiplasmin. Thrombosis diathesis is a dangerous feature associated with Cushing's disease, where hemostasis abnormalities have been described in around 54% of patients and consequent vascular events in 10% of patients.
Cushing's syndrome has multiple effects on bone metabolism. Elevated cortisol levels directly inhibit bone formation and indirectly influence the skeleton via effects on reproductive hormones, growth hormone, muscle and fat tissue, intestinal calcium absorption, and renal calcium excretion.
Excess glucocorticoids are thought to cause secondary osteoporosis through several mechanisms. Chronic glucocorticoid overproduction inhibits bone formation by directly impairing osteoblast differentiation and function, and promotes osteoblast and osteocyte apoptosis. While decreasing the production of osteoprotegerin, excessive glucocorticoid secretion can increase bone resorption by promoting osteoclast differentiation, maturation, and survival.
Skeletal fragility is a frequent complication of endogenous hypercortisolism, and fragility fractures may be the presenting clinical feature. The prevalence of osteoporosis in endogenous hypercortisolism as assessed by DXA or incidence of fragility fractures has been reported to be up to 50%.
The clinical features of Cushing's syndrome can be typical of other common disorders such as the metabolic syndrome, with insulin resistance, and polycystic ovary syndrome. Depression, mood dysregulation, sleep disturbance, and cognitive abnormalities are also observed. The rates for each of these symptoms vary widely across studies; however, depression is the most prevalent psychiatric disturbance in Cushing's syndrome.
Chronic endogenous glucocorticoid exposure determines several clinical complications, including metabolic complications such as visceral obesity, insulin resistance with glucose intolerance and diabetes mellitus, and dyslipidaemia; cardiovascular complications such as systemic arterial hypertension, atherosclerosis, thromboembolism; bone complications such as osteoporosis and osteoarthritis; and infective complications, ranging from an increase in susceptibility to infections up to a fatal sepsis, as well as neuropsychiatric disorders.
Prolonged exposure of every tissue in the body to an excess of cortisol produces Cushing's syndrome. Endogenous causes are ACTH-dependent, including Cushing's disease, ectopic ACTH-producing tumors, and CRH-producing tumors; or ACTH-independent, including cortisol-producing adrenal benign or malignant tumors, and rare micronodular adrenal hyperplasia.
Altered CRH secretion as well as qualitative changes in POMC (pro-opiomelanocortin) gene expression have been reported to be involved in the pathogenesis of Cushing's disease. Cushing's disease can be more atypical: secretion profiles are sometimes cyclic, with hypersecretion preceding a long period of normal secretion.
Cushing's disease is associated with increased mortality, substantial morbidity, and a notable impact on health-related quality of life. The pathophysiological levels of cortisol are associated with hypertension, diabetes, obesity, and early death.
Regarding electrolyte disruption, in a retrospective study of 202 patients diagnosed with Cushing's syndrome, 41.9% had hypokalemia and 15.0% had hypophosphatemia. The cortisol levels were negatively correlated with blood potassium, blood chlorine, and blood phosphorus.
Cushing's syndrome is a condition that may cause a variety of serious health risks; most recent evidence supports the persistence of increased morbidity and mortality even after long-term remission.
An interesting relationship exists between glucocorticoids and vitamin D values. Exogenous steroid therapy has been reported to be associated with vitamin D deficiency. The mechanism by which glucocorticoids reduce 25(OH)D levels is not direct, but indirect, regulating vitamin D receptor expression in many tissues and cells. Some authors have shown that treatment with dexamethasone in mice was associated with a decrease in 1Ξ±-hydroxylase (involved in the conversion of 25(OH)D3 to the active metabolite 1,25(OH)2D3) and an increase in 24-hydroxylase, which breaks down the active form of calcitriol, thereby reducing circulating 25(OH)D levels.
Glucocorticoid excess is known to result in vitamin D deficiency because it affects vitamin D metabolism and action by impairing the conversion of cholecalciferol into 25(OH)D.
Patients with Cushing's disease show many comorbidities such as cardiovascular disease, metabolic disease, diabetes mellitus, metabolic syndrome, dyslipidemia, obesity, osteoporosis/osteopenia and infections. Low serum 25(OH)D levels have significant skeletal and extra-skeletal consequences such as myopathy, high risk of fractures, and also affect the immune system and metabolism. All of these systems are impaired in patients with hypercortisolism, and vitamin D deficiency may provide a further aggravation of Cushing's disease comorbidities. Indeed, it may cause a reduced intestinal calcium absorption resulting in secondary hypocalcemia and hyperparathyroidism leading to bone demineralization.
Scientific Evidence: A study published in Nutrients (2022) included 50 patients with active Cushing's disease and 48 controls, examining serum 25-hydroxyvitamin D values and the response to 150,000 IU of cholecalciferol supplementation. Clinical data on the state of vitamin D metabolism in the state of glucocorticoid excess are quite scarce. Studies were very heterogeneous in design, some lacked a control group, and the absolute majority of the studies were performed before the introduction of vitamin D measurement standardization. Nevertheless, determining the optimal vitamin D treatment regimen in these high-risk patients is fairly relevant. Evidence strength: preliminary; findings from small observational studies, with a lack of large randomized controlled trials specifically in Cushing's disease.
Glucocorticoids reduce bone remodelling, augment urinary calcium excretion, and decrease intestinal calcium absorption. Elevated cortisol levels directly inhibit bone formation and indirectly influence the skeleton via effects on intestinal calcium absorption and renal calcium excretion. The combination of increased urinary calcium loss and decreased intestinal absorption creates a chronic negative calcium balance that contributes to progressive bone loss.
The mechanism involving bone resorption stimulated by excess PTH along with the direct inhibition of bone formation by glucocorticoid seems to play an important role in a progressive development of osteoporosis in Cushing's syndrome.
Potassium depletion is a recognized feature of hypercortisolism, particularly in more severe or ectopic forms. Severe hypertension with additional hypokalemia is more prevalent in ectopic Cushing's syndrome. In a large retrospective cohort, 41.9% of Cushing's syndrome patients had hypokalemia. Additionally, mineralocorticoids might indirectly limit insulin secretion by the pancreas as a result of hypokalemia; impaired insulin secretion can be caused by potassium depletion. The maintenance of adequate dietary potassium intake is therefore relevant to overall metabolic health in this context, though direct intervention trials in Cushing's disease are lacking.
The low-carbohydrate diet approach and, notably, the very low-calorie ketogenic diet (VLCKD), have several therapeutic applications, improving many metabolic disorders including diabetes mellitus, obesity, arterial hypertension, insulin resistance, and dyslipidaemia, as strongly supported by evidence. All of these metabolic disorders are present in patients with Cushing's disease.
The effects of a VLCKD on cortisol levels have not been yet clearly elucidated. It is widely known that meal macronutrients have a strong influence on cortisol concentrations, inducing an increase or decrease in them, as reported in many studies. Very few studies are currently available on the usefulness of a nutritional approach for the management of patients with Cushing's syndrome.
The primary objective of one published study was to assess the effects of a 3-week VLCKD and a 2-week low-carbohydrate ketogenic diet (LCKD), as adjunctive treatment to medical therapy for Cushing's disease, on salivary and serum cortisol, adrenal steroids, ACTH, and serum cortisol after a 1 mg dexamethasone suppression test (DST) and urinary free cortisol in 15 patients with Cushing's disease and 15 controls. Evidence strength: very preliminary; based on a small pilot study. The specific effects of ketogenic dieting on cortisol secretion in Cushing's disease remain under-studied.
Overall, hypertension is common in patients with Cushing's syndrome. Since hypercortisolism acts through mineralocorticoid-like mechanisms to promote sodium retention and fluid accumulation, dietary sodium restriction is a reasonable adjunct consideration for managing blood pressure and edema in this context, as discussed in clinical commentary. Evidence strength: Indirect; no randomized controlled trials have examined sodium restriction specifically in Cushing's disease; recommendations are extrapolated from general hypertension management principles.
Because dysglycemia and insulin resistance are prevalent in Cushing's disease, general dietary guidance from endocrine and clinical sources emphasizes whole foods with a lower glycemic index. Chronic hypercortisolism may have pleiotropic effects on all major peripheral tissues governing glucose homeostasis, leading to increased insulin resistance and decreased insulin secretion. Substituting refined carbohydrates with high-fiber foods has established benefits in improving insulin sensitivity and lipid profiles in metabolic syndrome broadly, though no dedicated trials have been conducted exclusively in Cushing's disease populations. Evidence strength: Indirect; based on applicability of dietary guidance from the broader literature on insulin resistance.
Traditional Use: Adaptogens such as Withania somnifera (ashwagandha) are commonly used in Ayurvedic medicine for stress relief and ameliorating HPA-axis dysfunction. In classical Ayurvedic texts, the root is used as a rasayana (rejuvenating tonic) and classified as an adaptogen intended to support the body's resilience against stress, fatigue, and depletion. Preparations traditionally include root powder in warm milk or decoctions.
Scientific Evidence: In a 60-day, randomized, double-blind, placebo-controlled study, the stress-relieving and pharmacological activity of an ashwagandha extract was investigated in stressed, healthy adults. Sixty adults were randomly allocated to take either a placebo or 240 mg of a standardized ashwagandha extract (Shoden) once daily. In comparison with the placebo, ashwagandha supplementation was associated with a statistically significant reduction in the HAM-A (P = .040). Ashwagandha intake was also associated with greater reductions in morning cortisol (P < .001) and DHEA-S (P = .004) compared with the placebo.
An RCT showed that aqueous WS extract (roots and leaves) safely reduces mild to moderate chronic stress at doses of 125 mg, 250 mg, and 500 mg/day for 8 weeks. These findings demonstrate the stress-reduction capabilities at the low dose of 125 mg/day, in a dose-dependent manner, via the modulation of the HPA axis.
These findings suggest that ashwagandha's stress-relieving effects may occur via its moderating effect on the hypothalamus-pituitary-adrenal axis. However, further investigation utilizing larger sample sizes, diverse clinical and cultural populations, and varying treatment dosages are needed to substantiate these findings.
Critical Caution: Crucially, all human trials of ashwagandha and cortisol have been conducted in healthy adults experiencing chronic psychosocial stress β not in patients with Cushing's disease. The cortisol-lowering mechanism studied in these populations involves modulation of a functioning HPA axis under chronic stress, which is physiologically distinct from the autonomous ACTH secretion by a pituitary adenoma that characterizes Cushing's disease. Furthermore, a recently published case report (PMC, 2025) documented that excessive doses and prolonged use of ashwagandha can lead to Cushingoid features and sustained suppression of the HPA axis. Evidence strength regarding Cushing's disease specifically: absent. All RCT evidence is in healthy, stressed adults and cannot be extrapolated to pituitary-driven hypercortisolism.
Traditional Use: Phosphatidylserine is not derived from a traditional herbal system. It is a phospholipid naturally occurring in cell membranes, isolated primarily from bovine brain or (in modern supplements) soy lecithin. Its use as a supplement originated in European pharmacological research in the 1980s and 1990s, initially for cognitive decline.
Scientific Evidence: Phosphatidylserine is a phospholipid that is a structural component of biological membranes. In studies, supplemental phosphatidylserine has been shown to improve mood and blunt the release of cortisol in response to physical stress. Early studies by Monteleone and colleagues (1990s) examined 800 mg/day PS and found attenuation of exercise-induced cortisol elevation in small samples of healthy men. These findings have not been replicated in large RCTs, and no trials have been conducted in Cushing's disease patients. Evidence strength: preliminary; limited to small studies in healthy subjects experiencing exercise-induced stress elevations of cortisol, not the pathological ACTH-driven hypercortisolism of Cushing's disease.
Traditional Use: Melatonin is an endogenous neurohormone; it has not been used in classical herbal traditions. Its use as a supplement developed from pineal gland physiology research in the twentieth century.
Scientific Evidence: Melatonin is secreted by the pineal gland and functions to regulate circadian rhythm and induce sleep. Melatonin circadian secretion in patients with pituitary- or adrenal-dependent Cushing's syndrome was shown to be significantly lower compared to healthy control groups. Studies have shown that nightly administration of 2 mg of melatonin increased the DHEA-S-to-cortisol ratio after 6 months of treatment. Evidence strength: very preliminary; these are small observational and open-label studies. The clinical significance of improving the DHEA-S/cortisol ratio via melatonin supplementation in the setting of autonomous pituitary adenoma-driven hypercortisolism is not established.
Traditional Use: While ascorbic acid has a long history as a dietary essential and has been used in nutritional therapy traditions, its targeted use for cortisol modulation is a modern evidence-based application, not part of traditional botanical medicine per se.
Scientific Evidence: Studies show that vitamin C and aspirin can attenuate and influence cortisol, inducing an anti-inflammatory response to prolonged exercise and stress. Vitamin C has been shown to reduce the elevation of cortisol in response to heavy exercise. In human studies, 3,000 mg of vitamin C daily mitigated a rise in blood pressure, cortisol, and subjective response to acute psychological stress. Evidence strength: weak to preliminary; the studies referenced address stress-induced cortisol spikes in healthy exercising subjects. No evidence exists for vitamin C influencing ACTH secretion from a pituitary adenoma or reducing pathological hypercortisolism in Cushing's disease.
Traditional Use: Rhodiola rosea has been used in traditional medicine in Scandinavia, Russia, and Central Asia as a tonic and adaptogen to combat fatigue and improve endurance. Holy basil (Ocimum tenuiflorum, also known as Tulsi) is a sacred plant in Ayurvedic medicine, used classically as an adaptogen, anti-stress herb, and immunomodulator.
Scientific Evidence: While human studies of both herbs support general adaptogenic and stress-reducing effects in healthy populations with psychological and physical stress, more research is needed to establish their efficacy and safety specifically for Cushing's syndrome. No clinical trials have examined either herb in patients with confirmed Cushing's disease. Evidence strength regarding Cushing's disease: absent.
An important and documented concern in the herbal supplement literature is the presence of undisclosed synthetic glucocorticoids in products marketed as "herbal." The use of exogenous glucocorticoids is a common cause of Cushing's syndrome. A published case described exogenous Cushing's syndrome caused by Binahong, an over-the-counter herbal supplement. A 54-year-old woman presented with weight gain, joint pain, hypertension, and poorly regulated type 2 diabetes. Physical examination revealed signs of steroid excess with a moon face and abdominal obesity. Synthetic glucocorticoid screening revealed a positive dexamethasone level in the herbal supplement. After stopping the supplement, her serum cortisol and dexamethasone levels returned to normal. This case emphasizes the importance of awareness for the use of supplements containing hidden glucocorticoids causing Cushing's syndrome.
Skeletal fragility is a common complication of endogenous Cushing's syndrome, although specific guidelines for managing bone health are lacking. In clinical practice studies, 22.9% of patients had osteoporosis during active disease; improved bone mineral density was observed within a year of Cushing's syndrome remission.
Weight-bearing exercise is broadly recommended for bone health in the context of glucocorticoid-induced osteoporosis. The Bone Health and Osteoporosis Foundation (BHOF) recommendations for prevention of osteopenia, osteoporosis, and bone fractures include performing weight-bearing and muscle-strengthening exercises and taking recommended amounts of daily calcium and vitamin D.
Hypercortisolism leads to pronounced protein catabolism and proximal muscle wasting. Proximal muscle weakness, wasting of the extremities with increased fat in the abdomen, torso, and face are characteristic of marked hypercortisolism. Adequate dietary protein intake is an important consideration in preserving lean body mass. While no specific trials in Cushing's disease have quantified optimal protein intakes, clinical guidance consistently emphasizes protein adequacy given the catabolic state.
Hypertension, impaired glucose tolerance, diabetes, dyslipidaemia, and visceral obesity are common cardiovascular risk factors in patients with Cushing's syndrome. Dietary approaches targeting each of these components β including sodium reduction, glycaemic management, lipid-lowering dietary patterns, and caloric balance β are relevant adjuncts within the overall management plan. Cardiovascular risk markers continue to be present long after cure of the hypercortisolemia, and the cardiovascular risk remains increased. This underscores the importance of sustained dietary vigilance even post-remission.
Most recent evidence supports the persistence of increased morbidity and mortality even after long-term remission. It is conceivable that the degree of normalization of the associated comorbid conditions depends on individual factors and characteristics of the conditions. These findings highlight the need for early recognition and effective management of patients with Cushing's syndrome, which should include active treatment of the related comorbid conditions.
Sleep disturbances are among the established clinical manifestations of Cushing's disease. Cortisol normally follows a diurnal rhythm β highest in the early morning and lowest at night. In Cushing's disease, this rhythm is profoundly disrupted, with persistently elevated late-night cortisol levels. Consistent sleep hygiene, management of co-occurring depression and anxiety, and avoidance of stimulants that further activate the HPA axis are discussed in clinical literature as supportive lifestyle measures, though evidence specific to Cushing's disease is limited.
Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with multiple RCTs and a 2024 meta-analysis confirming significant cortisol reductions in stressed individuals via HPA axis modulation. It has been studied in the context of adrenal steroidogenesis disorders including non-classical adrenal hyperplasia, where it reduced multiple adrenal precursor steroids. A published case report (PMC12824993) documented that high-dose ashwagandha caused HPA axis suppression producing Cushingoid features, demonstrating its potent cortisol-modulating activity. At 300β600 mg/day standardized extract, it reduces cortisol by approximately 20β28%.
HMR lignan (7-hydroxymatairesinol), derived from Norway spruce bark, is used alongside melatonin as a natural treatment approach for Cushing's disease. Like SDG, HMR inhibits cortisol-producing enzymes (3-beta-HSD and aromatase) by converting to enterolactone in the gut. University of Tennessee veterinary medicine recommends both HMR and SDG lignans for Cushing's treatment, citing equivalent efficacy in reducing cortisol levels. HMR has superior bioavailability compared to SDG, as gut conversion to enterolactone is more rapid and complete.
Melatonin has been studied for its ability to inhibit enzymes involved in cortisol biosynthesis in the adrenal glands, making it relevant to Cushing's disease management. Studies show melatonin circadian secretion is significantly lower in patients with pituitary- or adrenal-dependent Cushing's syndrome compared to healthy controls. Research (Pawlikowski et al., 2002) demonstrated that nightly administration of 2 mg melatonin increased the DHEA-S-to-cortisol ratio after 6 months. University of Tennessee veterinary studies found melatonin combined with lignans reduces adrenal steroid concentrations in Cushing's cases.
Phosphatidylserine (PS) is a phospholipid that modulates HPA axis activity at the pituitary level, blunting cortisol release. Clinical trials show that 600β800 mg/day significantly reduces cortisol response to stress, with one study finding up to a 35% reduction in cortisol area-under-the-curve. A double-blind placebo-controlled crossover study (PMC2503954; n=10 healthy males, 600 mg/day for 10 days) confirmed blunted cortisol response before and during exercise-induced stress. While studied primarily in stress-induced hypercortisolism rather than pituitary-driven Cushing's disease, PS is used clinically as an adjunct to reduce cortisol burden.
Secoisolariciresinol Diglucoside (SDG), the primary lignan from flaxseed hulls, is studied for Cushing's disease due to its ability to inhibit steroidogenic enzymes (3-beta-HSD and aromatase) involved in cortisol and estradiol production. University of Tennessee veterinary research found SDG lignans combined with melatonin lowered cortisol concentrations in dogs with Cushing's. The gut microbiota converts SDG to enterolactone and enterodiol, the active mammalian lignans. Both HMR and SDG lignans are recommended by the University of Tennessee for Cushing's treatment.
Retinoic acid, the active metabolite of vitamin A, has been studied in multiple preclinical and clinical trials specifically for Cushing's disease. It inhibits ACTH production by pituitary corticotroph tumor cells via POMC transcription suppression and exhibits antiproliferative effects on those tumors. A prospective multicenter human trial showed 43% of 7 patients normalized urinary free cortisol (UFC) at doses of 10β80 mg/day for 6β12 months. A second prospective trial of 16 patients found 25% achieved eucortisolemia and all showed cortisol reduction.
Vitamin D3 (cholecalciferol) supplementation has been specifically studied in Cushing's disease patients, who have significantly higher rates of vitamin D deficiency than matched controls. A clinical study (Nutrients 2022; n=50 active CD patients) found that vitamin D deficiency severity correlated with urinary free cortisol levels. Six weeks of cholecalciferol supplementation (150,000 IU load) significantly improved insulin sensitivity, raised 25(OH)D, lowered PTH, and reduced total cholesterol in CD patients. The study recommends vitamin D supplementation as a standard part of CD management.
Go back